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Bombesin receptor subtype 3 (BRS-3) is a G protein
coupled receptor whose natural ligand is unknown.
We developed potent, selective agonist (Bag-1,
Bag-2) and antagonist (Bantag-1) ligands to explore
BRS-3 function. BRS-3-binding sites were identified
in the hypothalamus, caudal brainstem, and several
midbrain nuclei that harbor monoaminergic cell
bodies. Antagonist administration increased food
intake and body weight, whereas agonists increased
metabolic rate and reduced food intake and body
weight. Prolonged high levels of receptor occupancy
increased weight loss, suggesting a lack of tachy-
phylaxis. BRS-3 agonist effectiveness was absent
in Brs3/Y (BRS-3 null) mice but was maintained
in Npy/Agrp/, Mc4r/, Cnr1/, and Leprdb/db
mice. In addition, Brs3/Y mice lost weight upon
treatment with either a MC4R agonist or a CB1R
inverse agonist. These results demonstrate that
BRS-3 has a role in energy homeostasis that comple-
ments several well-known pathways and that BRS-3
agonists represent a potential approach to the treat-
ment of obesity.
INTRODUCTION
Obesity, the consequence of energy intake greater than expendi-
ture, is a rapidly growing worldwide epidemic. Obesity contrib-
utes to serious diseases, including diabetes, dyslipidemia,
atherosclerotic vascular disease, and hypertension. Since the
discovery of leptin, great progress has been made in under-
standing the humoral signals and the neuronal and molecular
circuits that control energymetabolism, including themelanocor-
tin (a-MSH,MC4R,MC3R,AgRP), neuropeptideY, andendocan-
nabinoid pathways (Adan et al., 2008; Gao and Horvath, 2007).
The limited success to date in the pharmacotherapy of obesity
likely reflects the existence ofmultiple redundant and compensa-
tory pathways in energy homeostasis and thus highlights theCell Mneed for novel mechanisms for the treatment of obesity, working
either as monotherapy or in combination with other agents.
Bombesin receptor subtype 3 (BRS-3) is a member of the
bombesin receptor subfamily of GPCRs, which also includes
the neuromedin B- and gastrin-releasing peptide receptors
(NMBR and GRPR). It can signal via a Gq protein, thereby
increasing intracellular calcium. Despite its name and sequence
similarity, however, BRS-3 has a low affinity for bombesin, and
its natural ligand is unknown (Jensen et al., 2008). Molecules
that can activate human BRS-3 have been identified, including
synthetic peptides (Boyle et al., 2005; Mantey et al., 1997;Weber
et al., 2003; Zhang et al., 2009), natural peptides (Lammerich
et al., 2003), and small molecules (Carlton et al., 2008). Unfortu-
nately, these molecules are not sufficiently potent and selective
(Mantey et al., 2006), display significant species preferences (Liu
et al., 2002), or have suboptimal pharmacokinetic properties.
This deficiency has severely hampered pharmacological explo-
ration of BRS-3 function.
BRS-3 is primarily expressed in the brain (Jennings et al.,
2003; Liu et al., 2002; Ohki-Hamazaki et al., 1997a; Sano
et al., 2004; Weber et al., 1998; Whitley et al., 1999; Yamada
et al., 1999), but its biological functions were unknown until
Wada’s laboratory demonstrated that disruption of the Brs3
gene in mice caused a reduced metabolic rate, obesity, and
insulin resistance (Ohki-Hamazaki et al., 1997b). Caution should
be exercised, however, when physiological function is deduced
solely from the phenotype of a knockout mouse because
significant compensation and/or variation in neuronal growth
and connectivity can occur during development as a result of
germline gene disruption (Luquet et al., 2005; Pinto et al.,
2004). An example of a discordant result from a genetic versus
a pharmacologic approach is the neuropeptide Y Y5 receptor
(NPY5R). The Npy5r null mouse has a mildly obese phenotype
(Marsh et al., 1998), yet a NPY5R antagonist causes mild weight
loss, not gain (Erondu et al., 2006; Ishihara et al., 2006). Elucida-
tion of biological function in adult animals by pharmacologic
manipulation avoids developmental concerns and is an impor-
tant step in the validation of an obesity drug target.
In the present study, we describe the development of potent,
selective BRS-3 agonist and antagonist ligands that are suitable
for exploring thebiologyofBRS-3.Weuse these ligands toestab-
lish a role for BRS-3 in the regulation of food intake, metabolicetabolism 11, 101–112, February 3, 2010 ª2010 Elsevier Inc. 101
Figure 1. Treatment of Rats with Bantag-1 for 12 Days Increases
Food Intake and Body and Adipose Tissue Weight
On day 0, Sprague Dawley rats were implanted with osmotic pumps delivering
60 mg/day of Bantag-1 ICV as described in Experimental Procedures. Body
weights on day 0 were 307.3 ± 6.1 g for the vehicle (B) group and 313.9 ±
5.4 g for the Bantag-1-treated (d) group. Fat and lean mass were measured
by DEXA on day 0 (gray) and again on day 14 (white for vehicle, black for
Bantag-1). Data are mean ± SEM; n = 6–7 per group. *p < 0.05 versus vehicle.
See also Table S1.
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complementary to other regulators of energy homeostasis.
RESULTS
A BRS-3 Antagonist Ligand Increases Food Intake
and Body and Adipose Weight
Current knowledge of BRS-3 biological function comes chiefly
from knockout mice, with similar phenotypes reported in two
independently generated lines (Ohki-Hamazaki et al., 1997b)
(Ladenheim et al., 2008). To elucidate BRS-3 physiology without
genetic manipulations, we identified Bantag-1 as a potent and
selective BRS-3 antagonist. Bantag-1 is a peptide with a binding
IC50 for human and rodent BRS-3 of 2–8 nM and 1000-fold
selectivity over hNMBR and hGRPR, the two most closely
related GPCRs (Table S1 available online). Bantag-1 is not orally
bioavailable but is soluble in aqueous solutions, allowing paren-
teral administration. When infused intracerebroventricularly into
rats for 12 days, Bantag-1 increased food intake, with the cumu-
lative 2 week food intake being 12% higher (360 ± 15 g versus
321 ± 20 g with Bantag-1 versus vehicle, respectively; p = 0.01)
(Figure 1A). There was a progressive increase in body weight
gain (at 12 days: 69.4 ± 3.0 g versus 50.2 ± 2.0 g in Bantag-1
versus vehicle, respectively; p < 0.01) (Figure 1B). The extra
increase in body weight of the Bantag-1-treated group was
due to a selective increase in adipose mass (Figures 1C and
1D). Thus, antagonism of BRS-3 produces an obesity phenotype
consistent with that of the Brs3/Y mice.
A BRS-3 Agonist Reduces Food Intake and Increases
Metabolic Rate
We next identified a potent and selective agonist ligand of
BRS-3, Bag-1 (J.L. et al., unpublished data). Bag-1 has a binding
IC50 of 2.4–18 nM for BRS-3 (Table S1), with corresponding Ki
values of 17.4 and 3.7 nM for human and mouse, respectively.
Bag-1 is R 380-fold selective over hNMBR and hGRPR. Phar-
macokinetic properties of Bag-1 are presented in Table S2,
demonstrating that it is possible to use Bag-1 with oral dosing.
Oral administration (by gavage to ensure complete, accurate
dosing) of Bag-1 to C57BL/6 mice reduced food intake at
1 and 2 hr in a dose-dependent manner (Figure 2A). A similar
anorectic effect was not observed in Brs3/Y mice (Figure 2B),
demonstrating that Bag-1 suppression of food intake is BRS-3
mediated. Bag-1 was also effective in reducing food intake in
DIO rats (Figure 2C). No overt adverse behaviors were observed
with Bag-1 doses that reduce food intake in wild-type, but not
Brs3/Y, mice. The behavior of Brs3/Y mice was reported to
differ from that of wild-type controls in an elevated plus maze
(Yamada et al., 2002). However, Bag-1 did not affect rat behavior
in an elevated plus maze (Figure S1).
To conserve energy, small mammals, such as mice, adapt
to fasting by reducing their metabolic rate (30% in DIO mice)
(Figure 2D). This reduction was completely reversed by treat-
ment with Bag-1, despite continued fasting (Figure 2D), without
an effect on locomotor activity (Figure 2E). This relative increase
in metabolic rate persisted for 10 hr. The BRS-3 agonist also
increased fasting energy expenditure by 20% and 48% in
chow-fed and DIO C57BL/6 mice, respectively (Figure 2F). In
contrast, Bag-1 had no significant effect inBrs3/Ymice, demon-102 Cell Metabolism 11, 101–112, February 3, 2010 ª2010 Elsevier Instrating that the effect on metabolic rate is mediated via BRS-3.
During the indirect calorimetry measurements, Bag-1 had no
significant effect on respiratory quotient in lean, DIO, or Brs3/Y
mice (data not shown).
Bag-1 Reaches BRS-3 Sites in the Brain
To map the distribution of BRS-3 at the functional protein level,
we developed [3H]Bag-2, a potent, selective BRS-3 agonistc.
Figure 2. Bag-1 Treatment Reduces Food Intake and Increases
Fasting Metabolic Rate in Wild-Type, but Not Brs/Y, Mice
(A) Food intake in male C57BL/6N mice. Groups of mice (n = 6/group),
matched for initial body weight at 26.2 g, were treated with the indicated
oral doses of Bag-1. *p < 0.05 versus vehicle.
(B) Food intake in male Brs3/Y mice. Initial body weight means were 25.6 g in
the WT mice (solid bars) and 29.5 g in the Brs3/Y mice (hatched bars). Treat-
ment was with vehicle (open bars) or 100 mg/kg Bag-1 (closed bars); n = 14–
16/group. *p < 0.05 vehicle versus Bag-1 with genotype; #p < 0.05 vehicle WT
versus Brs3/Y.
(C) Food intake in Sprague Dawley rats. Male rats (15 weeks old, mean weight
of 535 g; n = 6/group) were dosed by oral gavage with 50 mg/kg of Bag-1
30–60 min before lights out, and food intake was monitored continuously.
Data were averaged into 1 hr bins; p < 0.05 for hours 3–7 and 10.
(D and E) Metabolic rate and locomotor activity time course. DIO C57BL/6
mice (average body weight 41 g; n = 4/group) were acclimatized to individual
housing in indirect calorimetry chambers for 3 days and shifted to thermoneu-
trality (29C) at 1400. At 1700, the 12 hr dark period started and food
was removed. At 0800 the next morning, vehicle (B) or 100 mg/kg Bag-1
(d) was dosed, and measurement of metabolic rate and locomotor activity
continued.
(F) Bag-1 increases fasting metabolic rate in a BRS-3-dependent manner.
Acclimatized mice were fasted overnight, and then metabolic rate measured
at thermoneutrality (29C) was measured from 1 to 6 hr after dosing vehicle
(open bars) or Bag-1 100 mg/kg (black bars). Group mean body weights for
the lean, DIO, and Brs3/Y groups were 31, 41, and 48 g, respectively. Each
vehicle/drug pair was measured at the same time; n = 4/group. *p < 0.01
versus vehicle. See also Table S2 and Figure S1.
Data are mean ± SEM in all panels.
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Cell Mradioligand with a mBRS-3 Kd of 2.6 nM (Table S1, Figure S2,
and S.H. et al., unpublished data). [3H]Bag-2-binding activity
was BRS-3 specific because it was competed effectively by
nonradioactive Bag-1 (data not shown) and binding was not
detectable in Brs3/Y mice (Figure 3). Moderate to abundant
BRS-3 binding (Figure 3, Table S3) was observed in various
hypothalamic nuclei (PVN, DMH, ARC, VMH, PH, Pe, MPA,
and LHA), forebrain (DB, Bst, and Acb) and caudal brain (PBN
andNTS) structures, the amygdala and thalamus. A novel finding
is the BRS-3 binding, albeit at relatively low levels, in nuclei con-
taining dopaminergic (ventral tegmental area, pars compacta of
substantia nigra and retrorubral field) and serotonergic (dorsal
and median raphe nuclei) neuron somas.
Because the effect of Bag-1 on food intake appears modest
(as compared to drugs such as taranabant, a CB1R inverse
agonist [Addy et al., 2008; Fong et al., 2007]), we investigated
whether this level of efficacy is due to an intrinsically modest
BRS-3 effect or to insufficient engagement of BRS-3 by Bag-1.
Availability of [3H]Bag-2 enabled us to develop an ex vivo
receptor occupancy assay to estimate in vivo brain BRS-3
occupancy due to orally administered Bag-1. With a 100 mg/kg
dose, brain BRS-3 occupancy was 80%, 28%, and < 10%
(n = 3), respectively, at 1, 6, and 20 hr after oral administration
in lean mice (Figure 4A). These results indicate that orally
administered Bag-1 does achieve high brain BRS-3 occupancy
in 1 hr. The transient kinetics likely reflects the compound’s
short half-life. Figure 4B shows the relationship between
plasma Bag-1 concentration and brain receptor occupancy
following oral administration. From the modeled fit, 50% and
90% receptor occupancy occurs at plasma concentrations of
0.21 mM and 4.06 mM, respectively. A plasma concentration ofetabolism 11, 101–112, February 3, 2010 ª2010 Elsevier Inc. 103
Figure 3. Anatomic Distribution of BRS-3 Binding in Mouse Brain
[3H]Bag-2 autoradiography images (21 month exposures) are from wild-type mouse brain (A-N) or BRS-3 knockout mouse brain (a-n). Anatomic locations were
determined according to Franklin and Paxinos (1997). Acb, nu accumbens; AHA, anterior hypothalamic area; Amyg, amygdale; ARC, arcuate hypothalamic nu;
Bst, bed nu of stria terminalis; CeA, central amygdaloid nu; CLi, caudal linear nu raphe; CM, central medial thalamic nu; DB, diagonal band; DMH, dorsomedial
hypothalamic nu; DR: dorsal raphe nu; ICj, Islands of Calleja; IMD, intermediodorsal thalamic nu; LA, lateroanterior hypothalamic nu; LHA, lateral hypothalamic
area; MeA, medial amygdaloid nu; MnR, median raphe nu; MPA, medial preoptic area; NTS, nu solitary tract; PAG, periaqueductal gray; Pe, periventricular hypo-
thalamic nu; PBN, parabrachial nu; PH, posterior hypothalamic nu; PV, paraventricular thalamic nu; PVN, paraventricular hypothalamic nu; RChL, retrochiasmatic
area, lateral; Re, reuniens thalamic nu; RRF, retrorubral field; Rt, reticular thalamic nu; SNC, substantia nigra, pars compacta; SuM, supramammilary nu; VMH,
ventromedial hypothalamic nu; VTA, ventral tegmental area; and VTM, ventral tuberomammillary nu. See also Table S3 and Figure S2.
Cell Metabolism
Treatment of Obesity with BRS-3 Agonists0.21 mM is 56-fold higher than the binding Ki, presumably
reflecting binding to plasma proteins, with the unbound fraction
being available for entry into the brain and binding to receptor.104 Cell Metabolism 11, 101–112, February 3, 2010 ª2010 Elsevier InBag-1 Reduces Body Weight
To investigate effects on body weight, we gave Bag-1 for 8 days
(vehicle, 30 mg/kg, or 100mg/kg each given 1 hr prior to and 5 hrc.
Figure 4. Receptor Occupancy of BRS-3 in the Brain
(A) Pseudocolor image of ex vivo [3H]Bag-2 binding in the hypothalamus of
mice at 1 hr after in vivo treatment with vehicle or Bag-1 (100 mg/kg, PO).
Reduction in radioligand binding reflects receptor occupancy by Bag-1.
Scale indicates relative intensity of radioactivity as quantified using a beta-
imager.
(B) Receptor occupancy as a function of plasma Bag-1 concentration. Data
were fit to a four-parameter Emax logistic function. The calculated fit parame-
ters (± SE) are: minimum 8.1 ± 16.2%, maximum 97.0 ± 11.3%, RO50 0.21 ±
0.08 mM, and Hill slope 0.83 ± 0.37. The calculated RO90 is 4.06 mM.
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lean, DIO, and Brs3/Y. The 30 mg/kg BID dose was increased
to 50 mg/kg BID after 4 days because no weight loss was
observed with 30 mg/kg BID. In the lean mice, the high dose
reduced body weight by 5% (p < 0.05), but there was no effect
of the low dose (Figure 5A). In the DIO cohort, the high and low
doses produced 11% (p < 0.05) and 6% (nonsignificant) weight
loss, respectively (Figure 5B). There was no significant weight
loss in the Brs3/Y mice (Figure 5C). In mice treated with
100 mg/kg of Bag-1, food intake was reduced in the WT and
DIO mice (11% and 23%, respectively; p < 0.05), but not in the
Brs3/Y mice (Figures 5D–5F). At the conclusion of the experi-
ment, the WT mice treated with 100 mg/kg Bag-1 exhibited
a significantly lower fat mass, with no change observed in the
Brs3/Y mice (Figures 5G and 5H). The mean plasma Bag-1
concentrations on day 8, 1 hr after dosing 100 mg/kg, were
2.6, 4.5, and 4.0 mM in the lean, DIO, and Brs3/Y mice, respec-
tively. The concentrations 6 hr after dosing were 0.27, 0.26, and
0.37 mM in these groups, respectively. These data suggest that
the lack of a response to drug by the Brs3/Y mice is not due
to inadequate exposure to Bag-1.Cell MTaken together, these data demonstrate that Bag-1 causes
weight loss (predominantly of adipose tissue) in a BRS-3-depen-
dent manner. DIO mice are more sensitive to the BRS-3 agonist
than are lean mice. The plasma drug levels indicate that near-full
brain occupancy was achieved shortly after dosing at 100mg/kg,
and a significant level of target engagement (>50%) was main-
tained for at least 12 hr daily under the BID dosing regimen.
Finally, no loss of efficacy occurred over the 8 day treatment
period, indicating that significant tachyphylaxis did not occur.
Bag-1 Acts Presynaptically to Increase IPSCs
To understand the cellular mechanisms affected by BRS-3
agonists, we studied inhibitory synaptic transmission in the
ARC. Rat ARC brain slices were prepared and neurons recorded
using the whole-cell voltage-clamp technique (Figure 6A). Acti-
vation of BRS-3 by Bag-1 increased the peak inhibitory postsyn-
aptic current (IPSC) amplitude 1.47 ± 0.42-fold (n = 5, p < 0.01;
Figures 6B and 6C). Titration with Bag-1 indicates an EC50
between 10 and 100 nM (Figure 6D), higher than that from the
cell-based assays. This difference is possibly due to reduced
ligand availability at BRS-3 sites in the brain slice and/or
decreased functional efficacy in the electrophysiological assay.
Accompanying the increased IPSC amplitude, the mean
paired-pulse ratio decreased from 1.34 ± 0.11 to 1.01 ± 0.14
(n = 5, p < 0.01; Figure 6E). In addition, Bag-1 increased the
frequency (from 2.97 ± 0.07 Hz to 6.04 ± 0.34 Hz; p < 0.01),
but not the amplitude (from 42.0 ± 5.4 pA to 41.4 ± 6.5 pA), of
the miniature IPSC (Figures 6F and 6G). Taken together, these
results suggest that activation of BRS-3 increases ARC inhibitory
synaptic transmission and achieves this effect by increasing
inhibitory neurotransmitter (presumably GABA) release proba-
bility via a presynaptic action.
BRS-3 Complements Other Regulatory Pathways
Pharmacologic monotherapy for the treatment of obesity is
currently inadequate, and there is much interest in using drug
combinations to enhance efficacy, for example by combining
therapies that target complementary pathways. We used
knockout mice to investigate the interactions of BRS-3 with
known regulators of energy homeostasis.
NPY and AgRP are orexigenic neuropeptides and important
mediators of leptin and ghrelin action (Chen et al., 2004; Ebihara
et al., 1999).Npy/Agrp/mice delay eating on re-exposure to
food after a fast, presumably due to lack of NPY (Bannon et al.,
2000). Bag-1 treatment of Npy/Agrp/ mice eliminated food
intake during 0–2 hr and 2–4 hr of the dark cycle (Figure 7A).
The effect in the Npy/Agrp/ mice was actually greater than
in the control mice, in which Bag-1 reduced food intake from
0–2 hr, but not from 2–4 hr. Thus, the Bag-1 anorectic effect
does not depend on NPY/AgRP and appears augmented in the
Npy/Agrp/ mice.
Melanocortin 4 receptor (MC4R) is another central regulator of
energy metabolism.Mc4r/mice are hyperphagic and severely
obese (Chen et al., 2000a; Huszar et al., 1997). Similar to the
Npy/Agrp/mice, Bag-1 treatment ofMc4r/mice reduced
food intake during 0–2 hr and 2–4 hr of the early dark cycle
(Figure 7B). The decreased food intake in the vehicle-treated
Mc4r/ mice (as compared to vehicle-treated wild-type mice)
at 2–4 hr may be due to stress from cage handling during theetabolism 11, 101–112, February 3, 2010 ª2010 Elsevier Inc. 105
Figure 5. Chronic Oral Treatment with Bag-1 Causes Mechanism-Based Weight Loss
(A–F) Male wild-type, DIO, and Brs3/Y mice (average initial body weight 32, 43, and 37 g, respectively) were treated with vehicle (black), 30 mg/kg BID Bag-1
(blue), or 100 mg/kg BID Bag-1 (red) for 8 days. In the 30 mg/kg groups, the dose was increased to 50 mg/kg after the fourth dose, indicated by the arrows. Body
weight change for wild-type, DIO, and Brs3/Y mice is shown in (A)–(C). Cumulative food intake for wild-type, DIO, and Brs3/Y mice is in (D)–(F).
(G and H) On day 8, fat and lean mass were measured in the wild-type and Brs3/Y groups by NMR (vehicle in black and 100 mg/kg Bag-1 in red).
*p < 0.05; n = 8/group. Data are mean ± SEM.
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mice are hypophagic, lean, and resist DIO (Cota et al., 2003;
Ravinet Trillou et al., 2004). Bag-1 efficacy for reducing food
intake was maintained in Cnr1/ mice from 0–2 hr (Figure 7C).
In leptin receptor-deficient Leprdb/db mice, Bag-1-mediated
reduction of food intake was also intact (Figure 7D). Similar to
the wild-type controls, Bag-1 did not affect 4–18 hr food
intake in any of the four knockout mouse strains. These results
suggest that NPY/AgRP, MC4R, CB1R, and leptin are unlikely
to be nonredundant downstream pathways mediating BRS-3’s
anorectic action.
Next, we examinedwhether BRS-3 is required for the effects of
MC4R and CB1R pharmacotherapy. Brs3/Y mice were treated
for 4 days with compound 2B, a MC4R agonist (Guo et al.,
2008). The Brs3/Y mice responded indistinguishably from wild-
type mice in reducing their food intake and body weight (from
adipose mass) (Figure 7E). Similarly, another cohort of Brs3/Y106 Cell Metabolism 11, 101–112, February 3, 2010 ª2010 Elsevier Inmice was treated for 4 days with AM251, a CB1R inverse agonist
(Thakur et al., 2005). The drug treatment reduced food intake
and body weight (from adipose mass) to a similar degree in the
Brs3/Y and wild-type mice (Figure 7F). Taken together, these
results indicate that regulation of energy homeostasis by BRS-3
is complementary to the MC4R and CB1R pathways.
DISCUSSION
We have developed novel BRS-3 agonist and antagonist ligands
that are sufficiently potent and selective to enable in vivo
exploration of the biology of BRS-3. Treatment with the antago-
nist increased food intake and body and adipose weight in
rats, consistent with the phenotype of the Brs3/Ymouse. Treat-
ment with a BRS-3 agonist had the opposite effect, reducing
food intake, increasing metabolic rate, and reducing body and
adipose weight.c.
Figure 6. Bag-1 Upregulates IPSCs via a Presynaptic Mechanism
(A) ARC neuron in which whole-cell voltage-clamp technique was performed to record IPSCs. Calibration bar, 10 um.
(B) (Top) IPSCs recorded before (control) and during perfusion with Bag-1. (Bottom) Control and Bag-1 traces in the top panel are overlaid or scaled to the control
(first IPSC peak).
(C) Summarized results showing that the peak amplitude of IPSCs in ARC neurons was significantly increased upon activation of BRS-3.
(D) A dose-response curve showing that the EC50 of Bag-1 in enhancing IPSCs is between 10 and 100 nM.
(E) The paired-pulse ratio (PPR) is significantly decreased upon activation of BRS-3.
(F) Miniature IPSCs before and during perfusion with Bag-1.
(G) Summarized results showing that the frequency, but not the amplitude, of mIPSCs in ARC neurons was increased by Bag-1.
Data in (C–E) and (G) are mean ± SE.
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Figure 7. Bag-1 Reduces Food Intake in Npy/Agrp/, Mc4r/,
Cnr1/, and Leprdb/db Mice and Brs3/Y Mice Respond to a MC4R
Agonist or a CB1R Inverse Agonist
(A) Male wild-type and age/weight-matched Npy/Agrp/ mice (10 months
old, average body weight of 27 g) were treated with Bag-1 (100 mg/kg, PO),
and food intake was measured at the indicated times as detailed in Experi-
mental Procedures.
(B–D)Mc4r/ mice (5 months old, average body weight for the wild-type and
Mc4r/ mice of 30 and 47 g, respectively), Cnr1/ mice (4 months old,
average body weight of 28 g), and Leprdb/db mice (6 weeks old, average
body weight for the wild-type and Leprdb/db mice of 20 and 29 g, respectively)
were tested as described for the Npy/Agrp/ mice. In A–D, hatched bars
represent vehicle treatment, and solid bars represent Bag-1 treatment of the
mice. Mouse genotype is indicated by color. Black, wild-type controls; red,
Npy/Agrp/; green, Mc4r/; blue, Cnr1/; and turquoise, Leprdb/db.
(E) Male, DIO wild-type, and Brs3/Y mice were dosed orally with MC4R
agonist 2B (20 mpk, BID) or vehicle for 4 consecutive days as detailed in
Experimental Procedures.
(F) AM-251 (5 mpk, QD) or vehicle was dosed to male, DIO wild-type, and
Brs3/Y mice.
*p < 0.05 versus vehicle, and +p < 0.1 versus vehicle. In all panels, data are
mean ± SEM; n = 6–8/group.
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108 Cell Metabolism 11, 101–112, February 3, 2010 ª2010 Elsevier InBody weight is regulated by a balance between energy
intake and expenditure. Food intake is under the control of
both homeostatic and nonhomeostatic (e.g., hedonic) mecha-
nisms (Gao and Horvath, 2007; Lutter and Nestler, 2009). The
present results support the following conceptualization of the
physiology of BRS-3. The BRS-3 ligand may be a peptide, like
the ligands for the GPCRs that are most similar to BRS-3. Spec-
ulatively, the BRS-3 ligand signals adequate energy supplies
and/or reduced hedonic drive by reaching BRS-3 sites, some
of which are in the hypothalamus/ARC. The BRS-3 agonist
acts presynaptically, presumably increasing GABAergic inhibi-
tory signals, and this signal is integrated with other inputs,
affecting food intake and energy expenditure. A notable feature
of the mouse experiments is that the BRS-3 agonist effects
(reduction in food intake, increase in metabolic rate, and weight
loss) are more pronounced in the obese state.
The precise mechanism(s), including neuron types and path-
ways, by which BRS-3 agonism regulates energy metabolism
remain unclear. Brain leptin, melanocortin, neuropeptide Y,
and endocannabinoid circuits are among the best-characterized
molecular pathways controlling energy homeostasis and serve
as common mediators of other energy-regulating hormones/
transmitters such as leptin and ghrelin (Chen et al., 2004; Seeley
et al., 1997). We found that a BRS-3 agonist is equally if not more
efficacious in four different knockout mice (Npy/Agrp/,
Mc4r/, Cnr1/, and Leprdb/db) than in wild-type mice and
that both a MC4R agonist and a CB1R inverse agonist maintain
efficacy in Brs3/Y mice. These data suggest that the BRS-3
mechanism involves circuitry that is complimentary to the path-
ways mentioned above.
The distribution of [3H]Bag-2 binding generally agrees with
that reported for BRS-3 mRNA in both mouse and rat (Ohki-
Hamazaki et al., 1997b; Yamada et al., 1999; Liu et al., 2002)
but differs from that reported for immunohistochemically
detected BRS-3 (Jennings et al., 2003). Strong binding signals
in hypothalamic nuclei such as PVN, DMH, LHA, and ARC,
along with caudal brainstem structures including PBN and
NTS, further support a role for BRS-3 in feeding behavior andc.
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ence of BRS-3 binding in several other brain regions suggests
its involvement in additional pathophysiological functions. A
notable difference between the binding and mRNA mapping
studies is the detection of BRS-3 binding in nuclei harboring
the cell bodies of monoaminergic neurons such as VTA/SNC/
RRF (dopaminergic), DR/MR (serotonergic), and tuberomam-
millary nucleus (histaminergic). This may be due to greater
sensitivity of the [3H]Bag-2 autoradiography technique or to
presynaptic BRS-3 binding, reflecting protein transport from
distant cell bodies. Dopamine, serotonin, and histamine have
been shown to be downstream mediators for leptin action in
the brain (Fulton et al., 2006; Yadav et al., 2009; Yoshimatsu,
2008). The presence of BRS-3 in the VTA and Acb, key struc-
tures involved in dopamine-mediated reward circuitry, also
raises the possibility that BRS-3 may regulate food intake via
both homeostatic and hedonic mechanisms (Morrison and
Berthoud, 2007). Linking BRS-3 to major monoaminergic
pathways identifies an area of BRS-3 biology worthy of further
investigation.
The availability of BRS-3 ligands will allow investigation of
aspects of BRS-3 biology that have not been explored. For
example, Brs3/Y mice develop insulin resistance as well as
obesity (Ohki-Hamazaki et al., 1997b); however, whether the
glycemic dysregulation is secondary to obesity remains unclear
(Fleischmann et al., 2000; Nakamichi et al., 2004). BRS-3 mRNA
has been reported in developing and injured lung (Shan et al.,
2004; Tan et al., 2006) and in certain lung cancer cell lines (Fathi
et al., 1993; Ryan et al., 1998), suggesting that BRS-3 may have
a role in growth, development, and/or tumorigenesis (Jensen
et al., 2008). Results from cell-based adhesion assays have
been invoked to suggest a role in adhesion and/or metastasis
(Hou et al., 2006). In addition, the Brs3/Y mice have been
reported to have phenotypes in assays of taste preference
(Yamada et al., 1999) and social response/anxiety (Yamada
et al., 2000, 2002). Presumably, novel facets of BRS-3 biology
will be discovered, driven by the availability of ligands.
Agonist-induced desensitization is commonly observed for
GPCRs. For example, rapid desensitization of b-adrenergic
receptors occurs in vitro following agonist stimulation even
at low (<10%) receptor occupancy (Rousseau et al., 1996). In a
primate model of Parkinson’s disease, dopamine D1 receptor-
mediated antiparkinsonian effect desensitizes with repeated
agonist administration (Blanchet et al., 1996). With continued
BRS-3 agonist treatment, one might also have expected tachy-
phylaxis or desensitization. However, treatment with Bag-1 for
8 days did not reveal appreciable body weight rebound, despite
dosing to achieve high levels of brain receptor occupancy, esti-
mated to be continuously > 50% for at least 12 hr of each day. In
fact, a correlation was observed between degree of weight
loss and levels of receptor occupancy, with maximal efficacy
achieved at continued BRS-3 occupancy (data not shown). In
the whole-cell recording experiments, increasing doses of
agonist did not result in tachyphylaxis, consistent with a lack of
desensitization. Similarly, additional studies in cell-based and
tissue systems confirmed that BRS-3 does not undergo robust
attenuation of signaling despite chronic stimulation (unpublished
data). Thus, BRS-3 both requires a high level of occupancy for
efficacy and does not undergo significant downregulation. ItCell Mremains to be seen whether these properties hold true with the
yet-to-be discovered endogenous ligand because the degree
of agonist-induced desensitization may be compound depen-
dent (Lewis et al., 1998).
Human (Rankinen et al., 2006) and nonhuman (Ashrafi et al.,
2003) genetic studies have identified a dauntingly large number
of potential molecular targets for the treatment of obesity.
Potential drug targets gain credence when they have large
effects, exhibit the right anatomic distribution, fit known human
physiology, and affect known comorbidities. The availability of
molecules suitable for pharmacologic investigation represents
a quantum leap in target evaluation, allowing pharmacologic
proof of concept. However, due to the limited success of
monotherapy for obesity, combination therapy is being investi-
gated vigorously. It has previously been noted that Brs3/Y
mice respond to treatment with the marketed obesity drug,
sibutramine, an uptake inhibitor of norepinephrine and serotonin
(Matsumoto and Iijima, 2003). Our finding that a BRS-3 agonist
regulates energy balance in a complementary manner to the
NPY, MC4R, CB1R, and leptin pathways provides opportunities
for rational combination strategies. Taken together, these
results demonstrate that pharmacological activation of BRS-3
represents a potential therapy for obesity, either alone or in
combination.
EXPERIMENTAL PROCEDURES
Compounds
Bag-1 (2-(4-{2-[5-(2,2-dimethylbutyl)-1H-imidazol-2-yl]ethyl}phenyl)pyridine;
compound 9 in J.L. et al., unpublished data), Bantag-1 (Boc-Phe-His-
4-amino-5-cyclohexyl-2,4,5-trideoxypentonyl-Leu-(3-dimethylamino)benzy-
lamideN-methylammonium trifluoroacetate), [3H]Bag-2 (40-{2-[5-(cyclopentyl-
methyl)-1H-imidazol-2-yl]-1,2-ditritium-ethyl}biphenyl-2-carboxylic acid, 44.2
Ci/mmol; Bag-2 is compound 21c in S.H. et al., unpublished data), [3H]Bag-3
(40-{2-[5-(cyclohexylmethyl)-1H-imidazol-2-yl](1,2-ditritium)ethyl}-4,5-difluor-
obiphenyl-2-carboxylic acid; Bag-3 is compound 3a in J.L. et al., unpublished
data), and the MC4R agonist (N-{1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-
phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]propyl}aceta-
mide; compound 2B in Guo et al., 2008) were synthesized at Merck Research
Laboratories as described.
Animals
Male C57BL/6Nmicewere purchased from Taconic, Germantown, NY. Unless
otherwise noted, animals were housed in a temperature- and humidity-
controlled environment with a 12 hr light/dark cycle and with food and water
available ad libitum. For the diet-induced obese model, mice were fed
a high-fat diet (BioServ S3282 or Research Diets 12492) for at least 14 weeks
before the study. Knockout mice were produced as described: Brs3/Y (Brs3 is
located on the X chromosome) (Ladenheim et al., 2008), Cnr1/ (Zimmer
et al., 1999), Npy/Agrp/ (Erickson et al., 1996; Qian et al., 2002),Mc4r/
(Chen et al., 2000b), and Leprdb/db (Jackson Laboratories, Bar Harbor, ME).
The knockout mice were backcrossed onto a C57BL/6 background at
least eight generations, except the Npy/Agrp/ mice, which were back-
crossed ten generations onto a 129/Sv background. All animal procedures
were performed in compliance with NIH guidelines and were approved
by the Merck Research Laboratories Institutional Animal Care and Use
Committee (Rahway, NJ).
BRS-3 Binding and Agonism Assays
Binding was performed similarly as described previously (Liu et al., 2002) using
membranes prepared from CHO or HEK293 cells overexpressing the indi-
cated receptor. [125I]-[D-Tyr6,b-Ala11,Phe13,Nle14]-Bombesin(6-14) (30 pM,
PerkinElmer, Boston, USA) was used for human BRS-3, NMBR, and GRPR
binding, and [3H]Bag-3 (660 pM) was used for rat and mouse BRS-3 binding.etabolism 11, 101–112, February 3, 2010 ª2010 Elsevier Inc. 109
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cells overexpressing BRS-3, using an aequorin bioluminescence assay as
described (Sano et al., 2004).
Food Intake and Body Weight Effect in Rats
Leanmale lateral ventricle-cannulated Sprague Dawley rats (Charles River Inc,
Wilmington, MA, USA) were fed regular Teklad rodent chow and implanted
with Alzet osmotic minipumps delivering 60 mg/day of Bantag-1 (0.5 ml/h of
5 mg/ml dissolved in 20% propylene glycol in water), and body weight and
food intake were recorded daily. In the Bag-1 experiment, DIO rats were
fed a moderate high-fat diet (Research diets D12266B) starting at 4 weeks
of age, and food intakewasmonitored continuously using a custom-built auto-
mated food intake monitoring system.
Brain BRS-3 Mapping and Occupancy in Mice
Mice were euthanized by CO2 asphyxiation, and brains were frozen in 40C
isopentane. For receptor autoradiography, 20 micron coronal brain sections
were cut at 17C and were thaw mounted onto glass slides (Fisher).
Following a 15 min preincubation in binding buffer (50 mM Tris.HCl [pH 7.4],
2 mM MgCl2, 1 mM CaCl2, 5 mM KCl, and 0.1% BSA), receptor binding was
initiated by incubating the slides in the same buffer containing 10 nM
[3H]Bag-2 for 2 hr at room temperature. Following three 4 min washes in
ice-cold buffer (50 mM Tris.HCl, 2 mM MgCl2, 1 mM CaCl2, 5 mM KCl,
and 0.05% Triton X-100) and a brief rinse in cold distilled water, the brain
sections were dried, and the bound [3H]Bag-2 was quantitated using a
beta-imager (Biospace, France). Alternatively, the slides were air dried and
exposed to X-ray film (Bio-Max, Kodak, NY) for 21 months at 4C, and the
resulting images were captured with an imaging analysis system (MCID/M2,
UK) and composed with Photoshop software (Adobe, Mountain View, CA).
Binding selectivity was confirmed by inhibition with 100-fold excess nonla-
beled compound and by using brain sections from Brs3/Y mice. Receptor
occupancy studies after oral dosing with Bag-1 were conducted as described
(Fong et al., 2007). In brief, brains were collected at prespecified times
after in vivo dosing and subjected to receptor autoradiography as described
above, except that the radioligand binding incubation was reduced to
30 min. Nonspecific binding was determined by incubation in the presence
of 1 mM unlabeled Bag-1. Maximum specific binding was defined as that in
vehicle-treated mice. Percent receptor occupancy by Bag-1 is calculated
as: [1  (binding of Bag-1 treated – nonspecific) / (binding of vehicle treated –
nonspecific)] 3 100.
Food Intake and Body Weight Effect in Mice
Acute: Male, chow-fed C57BL/6 mice were dosed orally with either vehicle or
Bag-1 at 20, 50, or 100 mg/kg at 30 min prior to onset of the dark cycle. At
5 min before the dark cycle, regular chow was switched to a moderate high-
fat diet (Research Diets 12451), and food intake was measured at 1, 2, and
18 hr postdosing. Chronic: Male wild-type, DIO, and Brs3/Y mice were indi-
vidually housed in a reverse light cycle (lights on 2000–0800) and conditioned
to oral gavage dosing with vehicle (10% Tween 80 in 0.25% methylcellulose)
for 7 days prior to the study. At 4 days prior to drug administration, Brs3/Y
and WT mice were switched to the same high-fat diet as the DIO group
(BioServe S3282). Bag-1 or vehicle was administered by gavage twice daily
(1 hr before and 5 hr after the onset of dark cycle) for 8 days, and body weight
and food intake were measured daily. At the end of the study, Bag-1 concen-
trations were measured in blood, and whole-body NMR was used to measure
body composition.
Metabolic Rate Measurement
Male wild-type, DIO, and Brs3/Ymice were individually housed in a 12 hr light
cycle and conditioned to oral gavage dosing with vehicle (10% Tween 80 in
0.25% methylcellulose). At 3 days prior to the study, mice were acclimatized
to individual housing in the metabolic chambers of an Oxymax System
(Columbus Instruments) equipped with a photobeam system to record motor
activity. At 1400 on the day prior to study, mice were shifted to thermoneutral-
ity (29C). At 1700, the 12 hr dark period started and food was removed. At
0800 the next morning, vehicle or 100 mg/kg Bag-1 was dosed and measure-
ment of metabolic rate continued. Changes in O2 and CO2 were recorded
every 17.5 min (70 s settle and 40 s measure). To compare the effect of treat-110 Cell Metabolism 11, 101–112, February 3, 2010 ª2010 Elsevier Inment in wild-type, DIO, and Brs3/Ymice, the period from 1 to 6 hr after dosing
was used, and readings associated with activity giving beam breaks greater
than 50 were excluded from the calculations.
Bag-1 Treatment of Npy/Agrp/,Mc4r/, Cnr1/, and Leprdb/db
mice
Male wild-type and age/weight-matched Npy/Agrp/,and Cnr1/ mice
and age-matched Mc4r/ andLeprdb/db mice were maintained in a 12:12
light/dark cycle with chow food ad libitum. Mice were dosed 1 hr prior to
lights out with vehicle or Bag-1 (100 mg/kg, PO). Food intake was measured
2, 4, and 18 hr following dose.
Electrophysiology
Hypothalamic brain slices were prepared as described (Dong et al., 2006). In
brief, Sprague Dawley rats of either sex at 22–28 postnatal days were anesthe-
tized with halothane and decapitated, and the brain was rapidly removed,
blocked, and placed in chilled (0C –6C) low-Ca2+ artificial cerebrospinal fluid
(ASCF) containing (in mM) 126 NaCl, 1.6 KCl, 0.625 CaCl2, 0.6 MgSO4,
1.25 NaH2PO4, 18 NaHCO3, and 11 D-glucose (gassed with 95% O2-5%
CO2 [pH 7.4]; osmolarity = 310 mosM). Coronal slices (260 mm) containing
the arcuate nucleus were cut with a vibratome (Leica, Germany). Slices were
incubated at 30C –32C in regular ACSF (containing [in mM] 126 NaCl,
1.6 KCl, 2.5 CaCl2, 1.3MgSO4, 1.25 NaH2PO4, 18 NaHCO3, and 11 D-glucose,
osmolarity = 300 mosM) bubbled with 95% O2-5% CO2 in a submersion
chamber and continuously perfused with heated ACSF (33C) at 2.5 ml/min.
Cells were visualized with an upright microscope using infrared illumination,
and cells in the medial and ventral ARC were selected for recording. Whole-
cell voltage-clamp recordings were made with a multiclamp 700B amplifier
(Molecular Device). A bipolar stimulating electrode was placed 100–300 mm
rostral to the recording electrode to stimulate excitatory afferents at 0.1 Hz.
For inhibitory postsynaptic current (IPSC) recordings, electrodes (2–6 MU)
contained (in mM) 100 Cs-methansulfate, 40 KCl, 10 HEPES, 0.4 EGTA,
2.0 MgCl2, 2.5 MgATP, and 0.25 Na3GTP (pH 7.2–7.4), 275–285 mosM.
Excitatory transmissions were blocked by adding 2 mM kynurenic acid in
bath, and miniature (m) IPSC recordings were obtained by adding additional
1 mM TTX in bath. Cells were held at –10 mV. Synaptic currents were recorded
for 5–15 min to ensure stability, and then Bag-1 was applied through perfusion
system for 5 min.
MC4R Agonist 2B/AM251 in Brs3/Y Mice
Male, diet-induced obese wild-type and age/sex-matched Brs3/Y mice were
dosed orally with either MC4R agonist 2B (20 mpk, BID) or vehicle (0.5%
methylcellulose) for 4 consecutive days. A second cohort of matched DIO
wild-type and Brs3/Y mice were dosed orally with either AM-251 (5 mpk, QD,
Tocris) (Gatley et al., 1996) or vehicle (0.25% methylcellulose/10% Tween 80)
for 4 consecutive days. Food intake and body weight were measured daily.
Statistics
Data are expressed as means ± SEM. One-way ANOVA with repeated
measures followed by the Dunnett post hoc test was used for comparing
multiple treatments versus the control group. Two-tailed t test (paired or
unpaired, as appropriate) was used in cases where only two groups were
compared.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and three tables and can be
found with this article online at doi:10.1016/j.cmet.2009.12.008.
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